MacroGenics Reports 25% Confirmed ORR in Phase 2 CCGC Interim Data
Lorigerlimab achieved a 25% confirmed ORR (4/16) in CCGC, with median PFS of 2.9 months and a six-month PFS rate of 33%. Enrollment of 20 more CCGC patients at 3 mg/kg Q3W is ongoing.